Open AccessSerum N ‐glycome alterations in breast cancer during multimodal treatment and follow‐up
Author(s) -
Saldova Radka,
Haakensen Vilde D.,
Rødland Einar,
Walsh Ian,
Stöckmann Henning,
Engebraaten Olav,
BørresenDale AnneLise,
Rudd Pauline M.
Publication year - 2017
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12105
Subject(s) - glycome , medicine , breast cancer , chemotherapy , inflammation , surgical oncology , oncology , glycan , glycosylation , cancer , immunology , glycoprotein , biology , microbiology and biotechnology , biochemistry
Using our recently developed high‐throughput automated platform, N ‐glycans from all serum glycoproteins from patients with breast cancer were analysed at diagnosis, after neoadjuvant chemotherapy, surgery, radiotherapy and up to 3 years after surgery. Surprisingly, alterations in the serum N ‐glycome after chemotherapy were pro‐inflammatory with an increase in glycan structures associated with cancer. Surgery, on the other hand, induced anti‐inflammatory changes in the serum N ‐glycome, towards a noncancerous phenotype. At the time of first follow‐up, glycosylation in patients with affected lymph nodes changed towards a malignant phenotype. C‐reactive protein showed a different pattern, increasing after first line of neoadjuvant chemotherapy, then decreasing throughout treatment until 1 year after surgery. This may reflect a switch from acute to chronic inflammation, where chronic inflammation is reflected in the serum after the acute phase response subsides. In conclusion, we here present the first time‐course serum N ‐glycome profiling of patients with breast cancer during and after treatment. We identify significant glycosylation changes with chemotherapy, surgery and follow‐up, reflecting the host response to therapy and tumour removal.